Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04103697
Other study ID # RuCorT-01
Secondary ID
Status Enrolling by invitation
Phase Phase 3
First received
Last updated
Start date August 1, 2019
Est. completion date August 2024

Study information

Verified date February 2021
Source Blokhin's Russian Cancer Research Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether 4 cycles of neoadjuvant CapOx chemotherapy is more effective than the upfront surgery in patients with intermediate risk CRM"-" mid and upper rectal cancer.


Description:

This trial aims to investigate the efficacy of neoadjuvant chemotherapy compared to upfront surgery in intermediate risk rectal cancer patients. This is a prospective multicenter open-label randomized phase III clinical trial. Patients will be randomized using an online randomization system to receive either 4 cycles of neoadjuvant CapOx (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 per os bid days 1-14) chemotherapy and surgery or surgery alone. A stratification will be performed based on N stage, tumor location in the middle or upper rectum and clinical center. Patients with cT3-4aN1-2M0, T4aN0M0 cancer in the upper rectum and сТ2-Т3bN1M0 (based on preoperative MRI) cancer in the middle rectum are included. All patients are potential candidates for adjuvant chemotherapy, according to preoperative staging. Chemoradiotherapy (50 Gy with concomitant capecitabine 825 mg/m2 per os bid on radiation days) will be performed for patients with tumor progression after neoadjuvant chemotherapy. The decision to proceed with adjuvant chemotherapy postoperatively will be based on pTNM stage in both treatment arms, according to actual treatment guidelines. The target accrual is 280 patients in each treatment arm (including 10% potential data loss) based on potential benefit of 10% 3-yr disease-free survival (75% vs 85%), α=0,05, power 80% in the experimental arm. An interim analysis is planned after 50% of the patients will reach a 3-year followup. Pelvic Magnetic Resonance Imaging (MRI) is performed in all patients for staging before and after neoadjuvant chemotherapy and before surgery. Pelvic MRI isbject to central review. Conduction of this study and data collection are controlled by a local institutional board.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 560
Est. completion date August 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Informed consent - Histologically verified colon rectal adenocarcinoma - cT3-4aN1-2M0 cancer of the upper rectum or ??2-?3bN1M0 cancer of the middle rectum (based on pelvic MRI) - Tumor more than 2 mm from mesorectal fascia (based on pelvic MRI) - Eastern Cooperative Oncology Group (ECOG) status 0-2 - Haemoglobin (HGB) > 90 g/L - Platelet Count (PLT) > 120x10*9/L - Serum creatinine < 150 µmol/L - Total bilirubin < 25 µmol/L Exclusion Criteria: - inability to obtain informed consent - distant metastases - synchronous or metachronous tumors - previous chemotherapy or radiotherapy - clinically significant cardiovascular disorders (myocardial infarction < 6 months before visit, stroke < < 6 months before visit, instable angina < 3 months before visit, arrhythmia, uncontrolled hypertension > 160/100 mm hg - clinically significant neurological disorders - previous neuropathy 2 or higher - current infection or heavy systemic disease - pregnancy, breastfeeding - ulcerative colitis - individual intolerance to treatment components - proven dihydropyrimidine dehydrogenase (DPD) deficiency - participation in other clinical trials - psychiatric disorders, which render patient unable to follow instructions or understand his/her condition - technical inability to perform pelvic MRI - inability of long-term followup of the patient

Study Design


Intervention

Drug:
Capecitabine
2000 mg/m2, bid, per os, days 1-14, 4 cycles
Oxaliplatin
130 mg/m2 iv day 1, 4 cycles
Capecitabine
825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
Radiation:
Radiotherapy
Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
Procedure:
Rectal cancer surgery
Laparoscopic or open partial or total mesorectal excision (based on exact tumor location and surgeons discretion)

Locations

Country Name City State
Russian Federation N.N.Blokhin Russian Cancer Research Center Moscow

Sponsors (1)

Lead Sponsor Collaborator
Blokhin's Russian Cancer Research Center

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary 3-year disease-free survival 3 years
Secondary Adjuvant chemotherapy compliance Proportion of patients who receive a complete course of adjuvant chemotherapy 6 months
Secondary Acute chemotherapy toxicity Toxicity measured according to NCI-CTCAE v.5.0 14 weeks
Secondary pathologic complete response rate (pCR) 1 month
Secondary local recurrence rate 3 years
Secondary 3-year overall survival 3 years
Secondary Operative morbidity Morbidity measured according to Clavien-Dindo classification 30 days
Secondary Neoadjuvant chemotherapy disease progression rate Proportion of patients with disease progression during neoadjuvant chemotherapy 14 weeks
Secondary Preoperative tumor-associated complications rate The rate of tumor-associated complications (bowel obastruction, bleeding etc) during neoadjuvant chemotherapy 14 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A